Meeting
2024 ASCO Genitourinary Cancers Symposium
Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS)
Authors
Benjamin L. Maughan
Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
Benjamin L. Maughan , Suneel Mundle , Mehregan Nematian-Samani , Xiayi Wang , Shawn Du , Yanfang Liu , Lawrence Ivan Karsh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 65)
DOI
10.1200/JCO.2024.42.4_suppl.65
Abstract #
65
Poster Bd #
B22
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings.
First Author: Daniel J. George
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ).
First Author: Benjamin H. Lowentritt
Poster
2022 ASCO Genitourinary Cancers Symposium
The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.
First Author: Kim N. Chi
Poster
2021 ASCO Annual Meeting
Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.
First Author: Umang Swami